Negotiation of insulin volume: the lowest price in China can be reduced by 10% and 90% of the purchase volume can be obtained!

"Before January 9, the enterprises participating in the on-site negotiation need to complete the registration." This is the regulation action proposed in the notice on negotiation of insulin drugs with volume issued by Wuhan joint purchasing office of pharmaceutical machinery on March 3 This is the latest progress since the beginning of December last year, when Wuhan officially started to purchase 45 varieties with large clinical dosage, such as omeprazole, lansoprazole, budesonide and levocarnitine, and for the first time, insulin was included in the volume procurement According to the previously released grouping and purchase volume information, the total agreed purchase volume was 1.7057 million, of which insulin like drugs accounted for 68% "Wuhan mode" once again makes the nearly 10 billion diabetes drug market boiling There are two main contents in the above notice: first, the detailed rules for negotiation of insulin carrying capacity have been clarified; second, the on-site negotiation enterprises for insulin drugs have been announced In the list, nine enterprises including Novo Nordisk, Lilly Suzhou pharmaceutical, Tonghua Dongbao pharmaceutical, UL, Yuheng pharmaceutical, Sanofi (Beijing) pharmaceutical, and Ganli pharmaceutical were divided into seven groups for negotiation So, how? Will it be like the negotiation of drug access to the national health insurance catalogue? After accumulating enough eyeballs of the industry, Wuhan city has given the answer: before June 30, 2019, the human insulin and insulin like drugs that are online in the "Hubei provincial centralized purchasing service platform for medical devices" and have transaction volume in medical institutions in Wuhan can participate in the negotiation of volume negotiation
From the perspective of negotiation rules, (1) if the products of the same group and the same enterprise have only one specification and the quotation is lower than 5% of the lowest price (excluding Fujian, Guangdong and Chongqing) of the national provincial network, 70% of the purchase volume of the products in Wuhan in 2018 will be the agreed purchase volume; if the quotation is lower than 10% of the lowest price, 90% of the purchase volume of the products in Wuhan in 2018 will be the agreed purchase volume; (2) the same group and the same enterprise If the product specifications of the enterprise are more than or equal to 2, and the quotation is lower than 5% of the lowest price (weighted decrease) of the national provincial network, 70% of the purchase volume of the group of products of the enterprise in Wuhan in 2018 will be the agreed purchase volume; if the quotation is lower than 10% of the lowest price of the country, 90% of the purchase volume of the group of products in Wuhan in 2018 will be the agreed purchase volume Note: in addition to the agreed purchase quantity, the remaining purchase quantity will be used as the substitute quantity If the decrease and weighted decrease are less than 5%, more than 50% of the purchase quantity of the product in Wuhan in 2018 will be used as the substitute quantity It is also clear in the document that in the same group, based on the absolute value of price reduction or weighted absolute value of price reduction, the top three enterprises are selected from the highest to the lowest to obtain the substitute consumption, the first enterprise gets 50% of the substitute consumption, the second enterprise gets 30%, and the third enterprise gets 20% of the substitute consumption In addition, the new diabetic patients who use insulin treatment every year in Wuhan area prefer to use insulin drugs with the highest absolute price reduction in the same group It can be said that the more attractive the market is, the more attractive it is Of course, it means lower price reduction How to bid not only can not lose the market share of the central province, but also can balance its own pricing system, how to determine the negotiation strategy, where to draw the bottom line and so on These days, the above-mentioned enterprises may not be too easy, and the mutual game has begun According to the requirements, enterprises need to register before January 9 The declaration enterprise calculates the price reduction range according to the consumption volume price relationship of the group and the reduction of the fund prepayment financial cost and other factors within the specified time, and then adopts the on-site negotiation method to negotiate the price The agreement between the enterprise and the experts within the specified time is deemed as the success of the negotiation What's more, patients who are using the non selected varieties will be given a three-month clinical replacement period According to the needs of patients, medical institutions above the second level can be selected to implement the replacement according to the preferred use method of new patients under the guidance of doctors If it is really because of clinical needs and can not replace the use of non selected varieties, the filing procurement shall be carried out in accordance with the principle of "one patient one filing" According to the data of mienei.com, in 2018, the market scale of chemical diabetes drugs in public hospitals in key provinces and cities rose to 6.77 billion yuan The market share of insulin and its analogues is over 37% In 2018, the sales of insulin and its analogues in public hospital terminals in key provinces and cities reached 2.5 billion yuan, and this market will grow rapidly with the promotion of policies and the large amount of market demand Data shows that in 2018, the total market share of the top ten brands of chemical insulin and its similar drugs in public hospitals in key provinces and cities remained at about 95% In the top ten brands, including Novo Nordisk, Lilly, Sanofi and other foreign enterprises accounted for 7 seats Market analysis: "as the main drug for diabetes - insulin, due to the expiration of several product patents, its biological similar drugs are booming, coupled with the efforts of domestic enterprises such as Ganli pharmaceutical, Tonghua Dongbao, Zhuhai federal, etc., the domestic market is in a glued state Several heavyweight insulin drug market shares have been gradually divided, such as the market performance of Sanofi's insulin glargine, Novo Nordisk's insulin aspart, Dieter insulin, human insulin and so on have declined In addition, there is no clear new progress in oral insulin in the second half of 2019 In the face of the coming tide of GLP-1 receptor agonists and SGLT2 drugs, it is crucial to consolidate the position of insulin market " This should also be the reason why Wuhan negotiation has attracted the attention of the outside world In the end, several companies are happy and worried, and they move the bench well